Bone Marrow Mononuclear Cell Therapy for Acute Myocardial Infarction: A Perspective from the CCTRN

Recent meta-analyses of cell therapy clinical trials have suggested that bone marrow mononuclear cell (BMC) delivery following acute myocardial infarction (AMI) may result in modest improvement in left ventricular LV function.1 In spite of this, the uniformly null findings emerging from the most current trials, TIME2, LateTIME3, and SWISS-AMI4 have prompted careful reconsideration of this approach.